Clinical Trials Logo

Filter by:
NCT ID: NCT02465567 Completed - COPD Clinical Trials

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

Start date: June 30, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.

NCT ID: NCT02464969 Completed - Clinical trials for Venous Thromboembolism

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Start date: November 22, 2015
Phase: Phase 4
Study type: Interventional

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

NCT ID: NCT02462928 Completed - Clinical trials for Macular Degeneration

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

CEDAR
Start date: June 25, 2015
Phase: Phase 3
Study type: Interventional

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

NCT ID: NCT02461589 Completed - Clinical trials for Diabetes Mellitus, Type 2

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Start date: September 21, 2015
Phase: Phase 2
Study type: Interventional

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

NCT ID: NCT02458638 Completed - Tumors Clinical Trials

A Study of Atezolizumab in Advanced Solid Tumors

Start date: July 16, 2015
Phase: Phase 2
Study type: Interventional

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

NCT ID: NCT02457728 Completed - Hernia, Inguinal Clinical Trials

Mesh Fixation and Closure of Peritoneum Following Laparoscopic Hernia Repair Using N-butyl Cyanoacrylate

Start date: January 2015
Phase: N/A
Study type: Interventional

Fixation of mesh and peritoneal closure during TAPP repair using n-butyl cyanoacrylate.

NCT ID: NCT02456740 Completed - Migraine Clinical Trials

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

STRIVE
Start date: July 17, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.

NCT ID: NCT02454803 Completed - Clinical trials for Upper Limb Spasticity

Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice

ULIS III
Start date: January 2015
Phase:
Study type: Observational

The primary purpose for this study is to understand the effect of botulinum toxin as a treatment integrated in the management of spasticity (stiffness) in the arm and/or hand, arising from any neurological condition. The study will look at the types of goals that people choose for treatment, and the extent to which these are achieved in different individuals.

NCT ID: NCT02454582 Completed - Clinical trials for Respiratory Insufficiency

Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation

Start date: January 2015
Phase: Phase 4
Study type: Interventional

SUMMARY AND AIM Background: The proper management of brain oxygenation is an essential component of all anaesthesiologic procedures. Nevertheless, the brain remains one of the least monitored organs in the perioperative phase and intensive care therapy. The INVOS Brain Oxymeter (IBO) is a reliable trend monitor for changes in regional cerebral oxygenation (rSO2). It is a current assumption that rSO2 directly correlates with Sa02, which can be influenced by different ventilation assistance systems, e.g. CPAP therapy. Objectives: The project aims at investigating changes of rSO2 in patients undergoing CPAP therapy for max. 15 minutes, in order to evaluate the effect of CPAP on cerebral oxygenation. Methods: NIRS measurement (with IBO) will be performed on the temporoparietal cortex on both sides of the head. The trial will consist of two parts i.e. with or without ventilatory assistance. The order of starting the study with or without CPAP therapy will be randomized. During each part the measurements will be performed until reaching a steady state (no change in rSO2 ± 2% for 3 min) but with a maximum duration of 15min. After each interval a BGA (blood gas analysis) will be performed.

NCT ID: NCT02452762 Completed - Hypovitaminosis D Clinical Trials

Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial

VITdAL-PICU
Start date: January 2016
Phase: Phase 2
Study type: Interventional

Documented roles for vitamin D in calcium homeostasis, cardiovascular and respiratory health, inflammation, innate immunity, and neuromuscular function have led to the hypothesis that deficiency might represent a modifiable risk factor for outcomes in critical illness. In recent years, dozens of adult studies have reported both high deficiency rates, and associations between lower vitamin D levels and organ dysfunction, health resource utilization, and mortality in the intensive care unit (ICU). More recently, similar observations have been made in critically ill pediatric populations. The cumulative body of basic science and clinical literature demonstrates that deficiency is common in critical illness and rapid normalization of vitamin D status could improve clinical outcomes and/or reduce health care costs. However, before conducting a phase III trial to determine whether restoration of vitamin D status improves outcomes in the PICU, the appropriate dosing regimen must be identified. Consequently, the investigators propose a phase II, double blind randomized controlled trial to determine a loading therapy dosing regimen that can safely and rapidly normalize vitamin D status in critically ill children.